Large population case-control studies with 10 years of follow-up improved the understanding of the association between CHIP and AML [65,66]; mutations in genes such as TP53, IDH1, and IDH2 demonstrated increased specificity and penetrance for the development of AML. This evidence concerns the gene STUB1 and acute myeloid leukemia.